Browsing Tag
New Zealand
133 posts
The great Indo-Pacific hedge: Why Asia’s allies are arming themselves and each other
China is rising and U.S. focus looks stretched. Indo-Pacific nations are building their own defence web before the next crisis.
UK and New Zealand discuss Ukraine, Hormuz and cost-of-living pressure as global instability hits households
Global instability is now a household cost issue. The United Kingdom and New Zealand linked Ukraine, Hormuz and the West Bank in one call.
Fisher & Paykel Healthcare (ASX: FPH) tops gainers as FY26 result lands and tariff refund opens
Fisher & Paykel Healthcare just beat. The harder question is whether a US Supreme Court tariff ruling hands FPH a refund or another year of uncertainty.
Jardine Matheson stock faces strategy test after A$3.4bn I-MED Radiology deal
Jardine Matheson is buying I-MED for A$3.4bn as radiology AI gains momentum. See why this healthcare deal matters now!
Bridgewest Ventures raises NZ$60.2m as New Zealand deep tech attracts offshore capital
New Zealand deep tech is undercapitalised. Bridgewest Ventures’ NZ$60.2m fund raise shows why offshore investors are circling.
Ventia Services (ASX:VNT) wins nine-year Yarra Valley Water renewal as investors weigh water infrastructure visibility
Ventia’s A$405m water renewal adds defensive backlog, but investors may ask whether essential services can offset wider contract-mix pressure.
Xero (ASX: XRO) climbs into FY2026 result as Melio integration becomes the central thesis test
Xero spent US$2.5bn on Melio. Shares are down 57% from the highs. The May 14 result is when bulls and bears find out who was right.
TechnologyOne (ASX: TNE) shares climb ahead of H1 FY2026 result as SaaS+ and AI thesis builds momentum
The Australian SaaS sell-off shed $1 trillion globally. TechnologyOne just upgraded guidance to 18-20% PBT growth. Either the market is wrong, or TNE is.
The a2 Milk Company recalls U.S. infant formula batches as cereulide detection sparks market sell-off
The a2 Milk Company faces investor scrutiny after a U.S. infant formula recall. Read how the risk could affect brand trust and strategy.
Algorae Pharmaceuticals (ASX: 1AI) raises A$4m to fund dual commercial and AI drug discovery growth strategy
Algorae Pharmaceuticals (ASX: 1AI) raises A$3.99m to scale AlgoraeRx commercial portfolio and advance AlgoraeOS AI drug pipeline. Read the full strategic analysis.